With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...

Complex sugar-protein molecules that sense external messages to help a cell grow or respond to its environment can now be ...

Anzen Industries is developing cell-free biomanufacturing technology to produce complex chemicals more efficiently and ...

Alteogen and Tesaro, a subsidiary of GSK, have entered an exclusive license agreement concerning a subcutaneous formulation of dostarlimab.

Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will ...

A growing body of research suggests that combining enzymes with biochar, a carbon-rich material made from agricultural and organic waste, could ...

SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT ...

While working as an engineer at Tesla, Niccolo Cymbalist never planned to start a business. But he’d been considering an idea ...

Oral presentation to highlight first-ever clinical evidence supporting use of a targeted GYS1 substrate reduction therapy, ...

Let’s say it’s 2036, and scientists are working on a new class of drugs. Today, for instance, pharmaceutical companies use ...

Scientists found a molecular brake that controls inflammation resolution. Blocking one enzyme reduced immune cells linked to ...